With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the ...

Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, ...

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...

The S&P 500 (SP500) closed in the green on Friday, after investors saw a week marked by earnings as well as global development involving news of a framework deal as Trump backed off tariff threats ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area. “We ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...